• Exo1 (B6876): Unraveling Selective Exocytic Pathway Inhibiti

  2026-04-28

  Explore the scientific underpinnings of Exo1, a methyl 2-(4-fluorobenzamido)benzoate inhibitor, and its unique impact on membrane trafficking inhibition. This article provides a rigorous, application-focused analysis distinct from existing resources.

• Nintedanib (BIBF 1120): Mechanism-Driven Innovation in Trans

  2026-04-28

  This thought-leadership article explores the mechanistic and translational value of Nintedanib (BIBF 1120), a triple angiokinase inhibitor, in advanced cancer and fibrosis research. By integrating evidence from landmark studies—including the heightened sensitivity of ATRX-deficient glioma cells to RTK/PDGFR inhibition—we provide actionable guidance for translational researchers aiming to exploit antiangiogenic and antifibrotic pathways. The article uniquely bridges molecular insights with experimental workflows, critically contrasts Nintedanib’s strengths and limitations, and offers a forward-looking perspective grounded in validated data.

• 2'3'-cGAMP (Sodium Salt): Applied Workflows for Immune Activ

  2026-04-27

  Harnessing 2'3'-cGAMP (sodium salt) enables precise activation of the cGAS-STING pathway for dissecting innate immune responses, disease models, and drug screening. This guide translates the latest neuroinflammation research into actionable protocols, troubleshooting tips, and advanced applications, empowering immunology labs with evidence-based best practices.

• MSH2 Loss Drives Cisplatin Resistance in Bladder Cancer Cell

  2026-04-27

  A whole-genome CRISPR screen identified MSH2 as a crucial mediator of cisplatin-induced apoptosis in muscle-invasive bladder cancer. These findings suggest that MSH2 protein level may serve as a predictive biomarker for platinum-based chemotherapy response and inform patient stratification strategies.

• Cell lysis buffer for WB and IP: Precision in Tumor Microenv

  2026-04-26

  Unlock high-fidelity protein extraction from complex tissues with Cell lysis buffer for WB and IP. Its robust protease and phosphatase inhibitor cocktail ensures preservation of native protein interactions—essential for advanced research on chemoresistance and signaling in oncology.

• Sisomicin’s In Vitro Activity vs. Clinical Isolates: Compara

  2026-04-25

  This study systematically evaluates the antimicrobial activity of sisomicin, a novel aminoglycoside antibiotic, against a wide range of clinical bacterial isolates. By benchmarking sisomicin’s efficacy relative to gentamicin, tobramycin, amikacin, butirosin, and kanamycin, the research provides critical reference data for antibiotic resistance studies and drug selection strategies.

• Kanamycin Sulfate: Water-Soluble Antibiotic for Advanced Mic

  2026-04-24

  Kanamycin Sulfate stands as a benchmark water-soluble antibiotic, offering high-purity, reproducibility, and workflow flexibility for microbiology and anti-infection research. This article distills state-of-the-art experimental protocols, troubleshooting strategies, and translational insights—from resistance selection to microbiome modulation—empowering next-generation laboratory applications.

• Calpeptin as a Calpain Inhibitor: Protocols and Research Ins

  2026-04-24

  Leverage Calpeptin’s nanomolar potency for precise modulation of calpain-driven pathways in fibrosis and inflammation research. This article delivers hands-on workflows, troubleshooting strategies, and actionable data for scientists advancing pulmonary fibrosis and cell death studies.

• Gepotidacin (GSK2140944): A New Era for Antibacterial Resear

  2026-04-23

  This thought-leadership article delivers strategic and mechanistic insights into Gepotidacin (GSK2140944), a first-in-class triazaacenaphthylene bacterial type II topoisomerase inhibitor. We bridge foundational enzymology, translational research protocol optimization, and the evolving competitive landscape, providing actionable guidance for researchers confronting multidrug-resistant pathogens. Drawing on primary literature, competitive analyses, and real-world workflow recommendations, this piece transcends standard product overviews—expanding the conversation and empowering the next generation of antibacterial innovation.

• Trichostatin A (TSA): Epigenetic Control of Regeneration and

  2026-04-23

  Explore the unique role of Trichostatin A (TSA) in epigenetic regulation, with advanced insights into its application in regeneration biology and cancer research. This article provides a deeper, practical perspective on TSA’s mechanism and translational value.

• Autophagy–Metastasis Prognostic Signature in Colorectal Canc

  2026-04-22

  Bai et al. developed a prognostic signature incorporating autophagy- and liver metastasis-associated genes, improving risk stratification and predicting immune microenvironment features in colorectal cancer. This integrative approach offers new perspectives for patient stratification and potential therapeutic targeting.

• EZ Cap™ Firefly Luciferase mRNA: Elevating Reporter Assays

  2026-04-22

  EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure sets a new standard for robust gene regulation reporter assays and in vivo bioluminescent imaging. Featuring optimized stability and expression, it empowers workflows with high sensitivity and reproducibility.

• BIIE 0246: Precision NeuroPeptide Y Y2 Receptor Antagonist U

  2026-04-21

  BIIE 0246 empowers researchers to dissect NPY Y2 receptor pathways with nanomolar precision, enabling advanced studies in synaptic, metabolic, and neurocardiac models. Its selectivity, robust in vivo efficacy, and clear protocol guidance make it the tool of choice for modulating presynaptic inhibition and feeding behaviors.

• Z-VAD-FMK in Apoptosis Pathway Research: Advanced Mechanisti

  2026-04-21

  Explore how Z-VAD-FMK, a potent pan-caspase inhibitor, enables advanced mechanistic dissection of apoptosis signaling. This article provides a unique, in-depth analysis of its role in apoptosis inhibition, integrating new insights from recent translational research.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Te

  2026-04-20

  DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe enables high-contrast, stable labeling of cell plasma membranes, supporting neuronal tracing, cell migration, and membrane dynamics studies. It should not be used for applications requiring water solubility or non-membrane organelle specificity, and protocol adherence is critical for optimal results.

16217 records 1/1082 page Next 12345 下5页 Last page